I would say that we looked at all the international candidates on the same shelf. CanSino was one of those international candidates. We were hoping for a domestic candidate and we very much placed equal emphasis on all the domestic candidates, but ultimately our goal was a safe and effective vaccine.
CanSino was thus one of the international candidates, and it was not given preference in any way, I would say.